SymBio Pharmaceuticals Limited
Other OTCTotal Valuation
SymBio Pharmaceuticals Limited carries a market capitalization of 26.38M, placing it among publicly traded companies globally. Its enterprise value stands at 5.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 26.38M |
| Enterprise Value | 5.93B |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 5.68 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 5.68 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 175.35 |
Financial Position
SymBio Pharmaceuticals Limited maintains a current ratio of 19.46, meaning it holds 19.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 352.45, indicating elevated leverage, while an interest coverage ratio of -97.23 demonstrates limited ability to service its debt obligations.
| Current Ratio | 19.46 |
| Quick Ratio | 14.67 |
| Debt / Equity | 352.45 |
| Debt / EBITDA | N/A |
| Interest Coverage | -97.23 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -148.04 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.33 |
Taxes
| Income Tax | 15.81M |
| Effective Tax Rate | N/A |
Stock Price Statistics
SymBio Pharmaceuticals Limited's stock has declined approximately -38.01111% over the past 52 weeks. The 50-day moving average sits at 0.56, while the 200-day moving average is 0.69.
| Beta (5Y) | N/A |
| 52-Week Price Change | -38.01111% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 0.69 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, SymBio Pharmaceuticals Limited generated 1.04B in revenue and converted that into -3.45B in net income, yielding earnings per share of -51.63. EBITDA reached -3.27B, while operating income came in at -3.27B.
| Revenue | 1.04B |
| Gross Profit | 744.93M |
| Operating Income | -3.27B |
| Pretax Income | -3.44B |
| Net Income | -3.45B |
| EBITDA | -3.27B |
| EBIT | -3.27B |
| Earnings Per Share (EPS) | -51.63 |
Margins
SymBio Pharmaceuticals Limited operates with a gross margin of 71.38, reflecting its pricing power and cost economics. The operating margin of -313.48 and net profit margin of -331.03 provide insight into operational efficiency.
| Gross Margin | 71.38 |
| Operating Margin | -313.48 |
| Pretax Margin | -329.51 |
| Profit Margin | -331.03 |
| EBITDA Margin | -313.48 |
Stock Splits
SymBio Pharmaceuticals Limited's most recent stock split took place on March 10, 2022 with a 4:1 split ratio.
| Last Split Date | 3/10/2022 |
| Split Ratio | 4:1 |
Scores
SymBio Pharmaceuticals Limited posts an Altman Z-Score of -42.93, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -42.93 |